Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN									
APPLICATION DATA SHEET (37 CFR 1.76) Title of SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION									
Invention	30B311101ED F11(AZINONE COMFOUNDS FOR THE TREATMENT OF INFLAMMATION								
As the below	named inventor(s), I/we declare that:								
This declarati	on is directed to:								
	The attached application, (and Preliminary Amendment, if applicable), or								
	Application No. <u>10/583,782</u> , filed on <u>06/19/2006</u>								
	as amended on (if applicable);								
I/we believe that sought;	at I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is								
I/we have revie amendment sp	wed and understand the contents of the above-identified application, including the claims, as amended by any ecifically referred to above;								
material to pate became availal	I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.								
	WARNING								
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.									
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.									
Full Name of Inventor(s)									
Inventor 1	Mark L. Boys								
Signature	Mark L. Boyo Citizen of us								
Inventor 2	Michael Clare								
Signature	Citizen of								
X Additional inventors are being named on next page									

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/01A (10-05)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)								
Title of Invention	UBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION							
As the below	named inventor(s), I/we declare that:							
This declarati	ion is directed to:							
	The attached application, (and Preliminary Amendment, if applicable), or (PCT/IB0H/03a38)							
	Application No. <u>10/583,782</u> , filed on <u>06/19/2006</u>							
	as amended on (if applicable);							
I/we believe the sought;	at I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is							
I/we have revie amendment sp	ewed and understand the contents of the above-identified application, including the claims, as amended by any secifically referred to above;							
material to pate became availa	I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.							
	WARNING							
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.								
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.								
Full Name of Inventor(s)								
Inventor 1	Mark L. Boys							
Signature	Citizen of Britian							
Inventor 2	Michael Clare							
Signature								
★ Additional	inventors are being named on next page							

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/01A (10-05)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)						
Title of Invention	SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION					
As the below named inventor(s), I/we declare that:						
This declaration	on is directed to:					
	The attached application, (and Preliminary Amendment, if applicable), or (PCT/IBO4/63238) Application No. 10/583,782, filed on 06/19/2006					
	as amended on (if applicable);					
I/we believe tha sought;	t I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is					
I/we have review amendment spe	wed and understand the contents of the above-identified application, including the claims, as amended by any ecifically referred to above;					
material to pate became availab	ge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be ntability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which be between the filing date of the prior application and the national or PCT International filing date of the part application.					
	WARNING					
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.						
be true, and fur	made herein of my/own knowledge are true, all statements made herein on information and belief are believed to ther that these statements were made with the knowledge that willful false statements and the like are punishable conment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing					
Full Name of Inventor(s)						
Inventor 3	Mark J. Mitton-Fry					
Signature	Mas Mitter Citizen of us					
☐ Additional	nventors are being named on					

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/81(06-03)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

			tion Numb	oer	10/583,782/ PCT/1B04/03238		
	Filing D	ate		06/19/2006			
POWER OF	First Na	med Inve	ntor	Mark L. Boys			
an	Title			SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION			
CORRESPONDE		Art Unit					
INDICATION	ON FORM	Examin	er Name				
		Attorne	y Docket i	Number	PC28082A		
I hereby appoint:							
Practitioners at Custor	mer Number	285	23	7			
OR OR	L			J			
Practitioners named b	elow:				•		
	Name			Registrat	on Number		
	· · · · · · · · · · · · · · · · · · ·						
as my/our attomey(s) or age	nt(s) to prosecute the appli	cation identified	above, an	nd to transac	all		
business in the United State							
Please recognize or change	the correspondence addre	ss for the above	e-identified	application	to:	į	
The above-mentioned	Customer Number.						
OR							
The address associate	ed with Customer Number						
OR							
Firm or							
Individual Name							
Address							
Address							
City			State		Zip		
Country			•				
Telephone		F	ах				
I am the:							
Applicant/Inventor.					·		
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).							
SIGNATURE of Applicant or Assignee of Record							
Name Mark L. Boys							
Signature	Made	B	10th Nov. 2006				
Date 10th Nov-2006			1000, 2000				
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple							
forms if more than one signatur			<u> </u>				
★Total of 3 forms are submitted. ★ Total of	ed.						

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/81(06-03)

Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

			Application Number			10/583,782 PCT/1B 04/03238		
	J	Filing Date			06/19/2006			
POWER OF	ATTORNEY	Ī	First Named Inventor			Mark L. Boys		
an	- - -		Title			SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION		
CORRESPONDE INDICATION		-	Art Unit					
INDICATION	JN FURIVI		Examiner	r Name	,			
			Attorney	Docke	et Number	PC28082A		
I hereby appoint:								
Practitioners at Custor	ner Number		2852	3				
OR	L							
Practitioners named be	elow:						1	
	Name		Registration Number					
]	
							┨ !	
]	
as my/our attorney(s) or age business in the United States	nt(s) to prosecute the appl	lication	identified a	ibove,	and to transact	t all		
Please recognize or change		ess for	the above-i	dentifie	ed application to	:o:	,	
The above-mentioned	Customer Number.							
OR								
The address associate	ed with Customer Number				_			
OR .							•	
						<u> </u>		
Firm or Individual Name								
Address								
Address								
City			St	ate		Zip		
Country								
Telephone			Fax	<u>. </u>				
I am the:								
Applicant/Inventor.								
Assignee of record of Statement under 37 C	the entire interest. See 37 CFR 3.73(b) is enclosed. (Fi	CFR 3	3.71. 'TO/SB/96).					
SIGNATURE of Applicant or Assignee of Record								
Name	Michael Clare	<u></u>	/ /	<u> </u>	7,			
Signature	1/4	The	111	12	THE			
Date 9th November 2006								
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.								
★Total of 3 forms are submitted.								
-								

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/81(06-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

			ion Numbe	er	10/583,782 PCT/1604/03238		
	Filing Da	ate		06/19/2006			
POWER OF A	ATTORNEY	First Nar	med Invent	tor	Mark L. Boys		
an		Title		•	SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION		
CORRESPONDE		Art Unit				The service of the se	
INDICATIO)N FORM	Examine	r Name				
		Attorney	Docket N	umber	PC28082A		
I hereby appoint:							
Practitioners at Custon	ner Number	2852	23				
OR	<u> </u>			1	,		
Practitioners named be	elow:						
	Name			Registrati	ion Number		
			 				
as my/our attorney(s) or ager business in the United States	nt(s) to prosecute the applications S Patent and Trademark Office	ion identified : connected t	above, and herewith.	I to transact	all		
	the correspondence address f			application 1	0:		
The above-mentioned				- F F	U .		
OR	Oddienier (tamper)						
	ad with Oustomer Number			\neg			
لــا	ed with Customer Number						
OR		<u></u>					
Firm or Individual Name							
Address							
Address							
City		s	state		Zip		
Country							
Telephone		Fa	ix				
I am the:							
Applicant/Inventor.		-					
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).							
SIGNATURE of Applicant or Assignee of Record							
Name	Mark J. Mitton-Fry						
Signature	Marz J. M	with	\rightarrow				
Date 13 November 2006							
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.							
★ *Total of 3 forms are submitted. ★ *Total of 3 forms are	ed.						

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. complete, including gathering, preparing, and submitting the completed application form to the CSFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.